These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 17172718)

  • 21. Does the BAFF dysregulation play a major role in the pathogenesis of systemic lupus erythematosus?
    Binard A; Le Pottier L; Saraux A; Devauchelle-Pensec V; Pers JO; Youinou P
    J Autoimmun; 2008; 30(1-2):63-7. PubMed ID: 18155417
    [TBL] [Abstract][Full Text] [Related]  

  • 22. To B or not to B: TNF family signaling in lymphocytes.
    Siegel RM; Lenardo MJ
    Nat Immunol; 2001 Jul; 2(7):577-8. PubMed ID: 11429537
    [TBL] [Abstract][Full Text] [Related]  

  • 23. B-cell stage and context-dependent requirements for survival signals from BAFF and the B-cell receptor.
    Mackay F; Figgett WA; Saulep D; Lepage M; Hibbs ML
    Immunol Rev; 2010 Sep; 237(1):205-25. PubMed ID: 20727038
    [TBL] [Abstract][Full Text] [Related]  

  • 24. CD5+ B lymphocytes in systemic lupus erythematosus and rheumatoid arthritis.
    Smith HR; Olson RR
    J Rheumatol; 1990 Jun; 17(6):833-5. PubMed ID: 1696993
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Living in context with the survival factor BAFF.
    Cancro MP
    Immunity; 2008 Mar; 28(3):300-1. PubMed ID: 18342003
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A role of FcgammaRIIB in the development of collagen-induced arthritis.
    Nakamura A; Takai T
    Biomed Pharmacother; 2004 Jun; 58(5):292-8. PubMed ID: 15194165
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The role of BAFF in immune function and implications for autoimmunity.
    Kalled SL
    Immunol Rev; 2005 Apr; 204():43-54. PubMed ID: 15790349
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A BAFF antagonist suppresses experimental autoimmune encephalomyelitis by targeting cell-mediated and humoral immune responses.
    Huntington ND; Tomioka R; Clavarino C; Chow AM; Liñares D; Maña P; Rossjohn J; Cachero TG; Qian F; Kalled SL; Bernard CC; Reid HH
    Int Immunol; 2006 Oct; 18(10):1473-85. PubMed ID: 16914508
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Understanding autoimmune disease: new targets for drug discovery.
    Balagué C; Kunkel SL; Godessart N
    Drug Discov Today; 2009 Oct; 14(19-20):926-34. PubMed ID: 19596080
    [TBL] [Abstract][Full Text] [Related]  

  • 30. B cell targeted therapies in autoimmune diseases.
    Isenberg DA
    J Rheumatol Suppl; 2006 May; 77():24-8. PubMed ID: 16652442
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Aberrant expression of BAFF in T cells of systemic lupus erythematosus, which is recapitulated by a human T cell line, Loucy.
    Yoshimoto K; Takahashi Y; Ogasawara M; Setoyama Y; Suzuki K; Tsuzaka K; Abe T; Takeuchi T
    Int Immunol; 2006 Jul; 18(7):1189-96. PubMed ID: 16740602
    [TBL] [Abstract][Full Text] [Related]  

  • 32. BAFF, APRIL and human B cell disorders.
    Tangye SG; Bryant VL; Cuss AK; Good KL
    Semin Immunol; 2006 Oct; 18(5):305-17. PubMed ID: 16916610
    [TBL] [Abstract][Full Text] [Related]  

  • 33. B cells move to centre stage: novel opportunities for autoimmune disease treatment.
    Browning JL
    Nat Rev Drug Discov; 2006 Jul; 5(7):564-76. PubMed ID: 16816838
    [TBL] [Abstract][Full Text] [Related]  

  • 34. BAFF overexpression is associated with autoantibody production in autoimmune diseases.
    Pers JO; Daridon C; Devauchelle V; Jousse S; Saraux A; Jamin C; Youinou P
    Ann N Y Acad Sci; 2005 Jun; 1050():34-9. PubMed ID: 16014518
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The current status of targeting BAFF/BLyS for autoimmune diseases.
    Ramanujam M; Davidson A
    Arthritis Res Ther; 2004; 6(5):197-202. PubMed ID: 15380033
    [TBL] [Abstract][Full Text] [Related]  

  • 36. B cell-directed therapies for autoimmune disease and correlates of disease response and relapse.
    Levesque MC; St Clair EW
    J Allergy Clin Immunol; 2008 Jan; 121(1):13-21; quiz 22-3. PubMed ID: 18206502
    [TBL] [Abstract][Full Text] [Related]  

  • 37. B lymphocytes in nonorgan-specific autoimmune diseases: implications for therapy.
    Youinou P; Pers JO
    Lupus; 2012 Nov; 21(13):1375-7. PubMed ID: 22976931
    [No Abstract]   [Full Text] [Related]  

  • 38. FcgammaRIIB as a modulator of autoimmune disease susceptibility.
    Tarasenko T; Dean JA; Bolland S
    Autoimmunity; 2007 Sep; 40(6):409-17. PubMed ID: 17729034
    [TBL] [Abstract][Full Text] [Related]  

  • 39. B cell epitope spreading: mechanisms and contribution to autoimmune diseases.
    Cornaby C; Gibbons L; Mayhew V; Sloan CS; Welling A; Poole BD
    Immunol Lett; 2015 Jan; 163(1):56-68. PubMed ID: 25445494
    [TBL] [Abstract][Full Text] [Related]  

  • 40. TNF ligands and receptors in autoimmunity: an update.
    Mackay F; Kalled SL
    Curr Opin Immunol; 2002 Dec; 14(6):783-90. PubMed ID: 12413530
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.